Respiratory Disease Vaccine Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

How Are the key drivers contributing to the expansion of the respiratory disease vaccine market?
The respiratory disease vaccine market is anticipated to grow as a result of the rising occurrence of tuberculosis. This type of respiratory affliction is caused by the bacterium Mycobacterium tuberculosis, primarily affecting the lungs and potentially causing complications in other bodily organs and systems. The growth in tuberculosis cases can spark initiatives to create and distribute vaccines for respiratory diseases in order to curb the spread of the disease. For example, the Centers for Disease Control and Prevention, a US government agency, reported in November 2023 that the United States saw 8,331 tuberculosis cases in 2022, signifying a 5.9% increase compared to 2021. The rate of occurrence climbed to 2.5 cases per 100,000 people, showing a 5.5% rise from the preceding year. Therefore, the escalating occurrence of tuberculosis is likely to boost the respiratory disease vaccine market. Driver for Respiratory Disease Vaccine Market: Smoking prevalence fuels the Growth of the Respiratory Disease Vaccine Market

Get Your Respiratory Disease Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

What growth opportunities are expected to drive the respiratory disease vaccine market's CAGR through 2034?
In recent times, the market size of respiratory disease vaccines has experienced a marginal increase. The value is projected to rise from $69.99 billion in 2024 to $70.9 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 1.3%. The expansion during the historic period can be traced back to the escalating occurrence of respiratory diseases, heightened awareness of vaccination among the public, initiatives towards public health, and escalating demand for vaccines that are efficient and more bearable.

The market for respiratory disease vaccines is projected to experience stable expansion in the upcoming years. The market is predicted to reach $79.16 billion by 2029, growing at a compound annual growth rate (CAGR) of 2.8%. Factors contributing to this growth during the projected timeline include an aging population, increased healthcare expenditure, investment in vaccines, and readiness for pandemics. The forecast period will also witness trailblazing advancements in vaccines, joint research efforts, progress in vaccine development, and drug approval.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

What are the emerging trends shaping the future of the respiratory disease vaccine market?
Leading businesses in the respiratory disease vaccine market are focusing on product innovation to increase their effectiveness and offer advanced solutions for the prevention and treatment of respiratory disease infections. As an example, Pfizer Inc., a pharmaceutical firm based in the United States, won approval from the Food and Drug Administration (FDA) in May 2023 for its ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine. The vaccine is targeted at the prevention of lower respiratory tract disease caused by the respiratory syncytial virus in individuals aged 60 and above. ABRYSVO is a vaccine without adjuvant that includes a pair of preF proteins that have been specially designed to boost immunity to RSV A and B types and have shown clinically to be safe and effective.

Which growth-oriented segments of the respiratory disease vaccine market are leading the industry's development?
The respiratory disease vaccine market covered in this report is segmented -

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
3) By Age: Infant, Adolescent, Adult
4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:
1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12924

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What companies are at the forefront of innovation in the respiratory disease vaccine market?
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

What Is Covered In The Respiratory Disease Vaccine Global Market Report?

•Market Size Forecast: Examine the respiratory disease vaccine market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the respiratory disease vaccine market for a structured understanding.
•Key Players Overview: Analyze major players in the respiratory disease vaccine market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the respiratory disease vaccine market.
•Segment Contributions: Evaluate how different segments drive overall growth in the respiratory disease vaccine market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the respiratory disease vaccine market.
•Industry Challenges: Identify potential risks and obstacles affecting the respiratory disease vaccine market.
•Competitive Landscape: Review strategic developments in the respiratory disease vaccine market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.